Search
 

Are new cancer drugs worth the price?

In a study of 48 cancer treatment drugs, researchers concluded that more than half had been approved for use in an absence of any benefits for either longer survival or quality of life benefits.

By Dan Cook | Updated on October 09, 2017
A recent study suggests that many new cancer drugs being concocted in the lab are released to the public without any proof of efficacy. (Photo: Shutterstock)

Are many new cancer drugs being concocted in the lab and released to the public without any proof of their efficacy? A recent study that examined the effect of drugs released since 2009 found that more than half had showed no benefits in terms of survival rate of quality of life of the patients.

A study of evidence of benefits of cancer drugs approved by European Medicines Agency published in the British Journal of Medicine examined the clinical evaluations done prior to the approval of 48 cancer treatment drugs. After pouring through the evaluations, the researchers concluded that more than half had been approved for use in an absence of any benefits for either longer survival or quality of life benefits.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Dan Cook

Dan Cook

Dan Cook is a journalist and communications consultant based in Portland, OR. During his journalism career he has been a reporter and editor for a variety of media companies, including American Lawyer Media, BusinessWeek, Newhouse Newspapers, Knight-Ridder, Time Inc., and Reuters. He specializes in health care and insurance related coverage for BenefitsPRO.

More from this author

Recommended Stories

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2024 ALM Global, LLC. All Rights Reserved.